Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Natl J Maxillofac Surg ; 13(2): 283-288, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36051795

RESUMEN

Objective: The objective is to evaluate the efficacy of prophylactic single intravenous dose of palonosetron in the management of postoperative nausea and vomiting (PONV) following oral and maxillofacial surgical interventions performed through an intraoral approach under general anesthesia (GA). Materials and Methods: A prospective study was conducted on 100 subjects who underwent intraoral surgical procedures for the management of maxillofacial trauma, pathology, dentofacial anomalies, and deformities under GA. All subjects received a prophylactic single intravenous dose of 0.075 mg palonosetron along with premedication. Predisposing factors for PONV such as patient age, gender, Apfel risk score, history of motion sickness, smoking, type of procedure, and administration of postoperative opioids were taken into consideration. All the patients were monitored for PONV for the 1st 24 h postoperatively (PO). First, at an interval of 30 min for 1st 4 h and then at every 2 h interval for next 8 h followed by monitoring every 6 h interval till 24 h. Time and frequency of rescue medication were noted. Results: Seventy-nine percentage subjects did not have PONV. 15% subjects had a single episode of vomiting PO which could be attributed to multiple intra oral surgical sites performed as well as longer duration of exposure to anesthetic agents in addition to providing opioid analgesics for the management of postoperative pain. Only 6% subjects needed rescue antiemetic drug. Palonosetron did not show any significant changes in cardiac status and serum profile. Conclusion: Palonosetron is effective in the management of PONV for maxillofacial surgical procedures performed through an intraoral approach under GA.

2.
J Family Med Prim Care ; 9(11): 5779-5782, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33532433

RESUMEN

Adenoid squamous cell carcinoma (ASCC) is a variant of squamous cell carcinoma. As this variant is rare it is difficult to distinguish it from other variants of squamous cell carcinoma. It commonly originates in the head and neck region as these parts are highly exposed to the sunlight. There are very few cases reported in the literature. Here we report a case in a 30-year-old male who reported with a nodular lesion over the upper lip with no unusual signs, which was confirmed as adenoid squamous cell carcinoma after various histopathological tests.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...